Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Filippo Migliorini, Giorgia Colarossi, Alice Baroncini, Jörg Eschweiler, Markus Tingart & Nicola Maffulli. (2021) Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion. Expert Review of Clinical Pharmacology 14:1, pages 105-119.
Read now
Read now
Santiago Palacios. (2010) Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Current Medical Research and Opinion 26:7, pages 1553-1563.
Read now
Read now
Farook Al-Azzawi. (2008) Prevention of postmenopausal osteoporosis and associated fractures: Clinical evaluation of the choice between estrogen and bisphosphonates. Gynecological Endocrinology 24:11, pages 601-609.
Read now
Read now
Articles from other publishers (43)
Emma O. Billington, Rebecca C. Miyagishima, Charley Hasselaar & Mubashir Arain. (2023) Women’s perspectives regarding osteoporosis, fracture risk, and pharmacologic treatment: a cross-sectional study. Osteoporosis International 34:12, pages 2069-2076.
Crossref
Crossref
Aria Ahadzadeh Ardebili, Timothy Fu, Nicole Dunnewold, Fariba Aghajafari & Emma O. Billington. (2023) Bisphosphonates Preserve Bone Mineral Density and Suppress Bone Turnover Markers in Early Menopausal Women: A Systematic Review and Meta‐Analysis of Randomized Trials. JBMR Plus 7:6.
Crossref
Crossref
Mina Nicole Händel, Isabel Cardoso, Cecilie von Bülow, Jeanett Friis Rohde, Anja Ussing, Sabrina Mai Nielsen, Robin Christensen, Jean-Jacques Body, Maria Luisa Brandi, Adolfo Diez-Perez, Peyman Hadji, Muhammad Kassim Javaid, Willem Frederik Lems, Xavier Nogues, Christian Roux, Salvatore Minisola, Andreas Kurth, Thierry Thomas, Daniel Prieto-Alhambra, Serge Livio Ferrari, Bente Langdahl & Bo Abrahamsen. (2023) Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ, pages e068033.
Crossref
Crossref
Michelle Gates, Jennifer Pillay, Megan Nuspl, Aireen Wingert, Ben Vandermeer & Lisa Hartling. (2023) Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools. Systematic Reviews 12:1.
Crossref
Crossref
Evrydiki Kravvariti, Maria-Iosifina Kasdagli, Konstantina Maria Diomatari, Pelagia Mouratidou, Kosmas Daskalakis, Dimos D. Mitsikostas, Petros P. Sfikakis & Maria P. Yavropoulou. (2023) Meta-analysis of placebo-arm dropouts in osteoporosis randomized-controlled trials and implications for nocebo-associated discontinuation of anti-osteoporotic drugs in clinical practice. Osteoporosis International 34:3, pages 585-598.
Crossref
Crossref
Alejandra B. Osorio. (2022) ¿(No) “solo Madrid es Corte”?: la cabeza que gobierna un imperio de Cortes. Culture & History Digital Journal 11:1, pages e002.
Crossref
Crossref
George A Wells, Shu-Ching Hsieh, Carine Zheng, Joan Peterson, Wenfei Liu, Shannon E Kelly & Peter Tugwell. (2022) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2022:7.
Crossref
Crossref
Qin Hu, Xun Pan, Yaxian Liang, Hongdan Xu, Jinning Gu, Wenting She & Huixu Xie. (2022) Comparative efficacy and safety of bisphosphonate therapy for bone loss in individuals after middle age: A systematic review and network meta-analysis. Nano TransMed 1:1, pages 9130003.
Crossref
Crossref
Filippo Migliorini, Nicola Maffulli, Giorgia Colarossi, Jörg Eschweiler, Markus Tingart & Marcel Betsch. (2021) Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. Journal of Orthopaedic Surgery and Research 16:1.
Crossref
Crossref
Filippo Migliorini, Nicola Maffulli, Filippo Spiezia, Giuseppe Maria Peretti, Markus Tingart & Riccardo Giorgino. (2021) Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review. Journal of Orthopaedic Surgery and Research 16:1.
Crossref
Crossref
Filippo Migliorini, Nicola Maffulli, Filippo Spiezia, Markus Tingart, Peretti Giuseppe Maria & Giorgino Riccardo. (2021) Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review. Journal of Orthopaedic Surgery and Research 16:1.
Crossref
Crossref
Su-li Dong, Yongqiang Jiao & Hai-liang Yang. (2021) Effectiveness of bisphosphonates on bone mineral density in osteopenic postmenopausal women. Medicine 100:31, pages e26715.
Crossref
Crossref
Jianbiao Lin, Shaofeng Ma, Cong Zhu, Changqing Chen, Weibin Lin, Canbin Lin, Guofeng Huang & Zhenqi Ding. (2020) Circular RNA atlas in osteoclast differentiation with and without alendronate treatment. Journal of Orthopaedic Surgery and Research 15:1.
Crossref
Crossref
Katerina Trajanoska & Fernando Rivadeneira. (2020) Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders. Frontiers in Endocrinology 11.
Crossref
Crossref
Sarah Davis, Emma Simpson, Jean Hamilton, Marrissa Martyn-St James, Andrew Rawdin, Ruth Wong, Edward Goka, Neil Gittoes & Peter Selby. (2020) Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technology Assessment 24:29, pages 1-314.
Crossref
Crossref
Mone Zaidi, Ayesha Khan, Ashutosh Sharma, Igor Ataebiekov, Elina Hadelia, Funda Korkmaz, Jameel Iqbal, Tony Yuen & Daria Lizneva. 2020. Encyclopedia of Bone Biology. Encyclopedia of Bone Biology
503
518
.
Mone Zaidi, Tony Yuen, Se-Min Kim, Jameel Iqbal & Daria Lizneva. 2020. Encyclopedia of Bone Biology. Encyclopedia of Bone Biology
1
9
.
Mary L Bouxsein, Richard Eastell, Li-Yung Lui, Lucy A Wu, Anne E de Papp, Andreas Grauer, Fernando Marin, Jane A Cauley, Douglas C Bauer & Dennis M Black. (2019) Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. Journal of Bone and Mineral Research 34:4, pages 632-642.
Crossref
Crossref
Daria Lizneva, Tony Yuen, Li Sun, Se-min Kim, Ihor Atabiekov, Lubna Bashir Munshi, Sol Epstein, Maria New & Mone Zaidi. (2018) Emerging concepts in the epidemiology, pathophysiology, and clinical care of osteoporosis across the menopausal transition. Matrix Biology 71-72, pages 70-81.
Crossref
Crossref
Stewart G. Albert & Supraja Reddy. (2017) Clinical Evaluation of Cost Efficacy of Drugs for Treatment of Osteoporosis: A Meta-Analysis. Endocrine Practice 23:7, pages 841-856.
Crossref
Crossref
G. Wang, L. Sui, P. Gai, G. Li, X. Qi & X. Jiang. (2017) The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment. Bone & Joint Research 6:7, pages 452-463.
Crossref
Crossref
Hirotaka NAGASHIMA, Masashi HIRAYAMA, Hiroaki OHISHIIchiro OIKAWA. (2017) <b>Optimizing a Single Monthly Dose of Risedronate Based on its Weekly Dose in Healthy Japanese Postmenopausal Women </b>. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 48:4, pages 121-129.
Crossref
Crossref
Sarah Davis, Marrissa Martyn-St James, Jean Sanderson, John Stevens, Edward Goka, Andrew Rawdin, Susi Sadler, Ruth Wong, Fiona Campbell, Matt Stevenson, Mark Strong, Peter Selby & Neil Gittoes. (2016) A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment 20:78, pages 1-406.
Crossref
Crossref
Jean Sanderson, Marrissa Martyn-St James, John Stevens, Edward Goka, Ruth Wong, Fiona Campbell, Peter Selby, Neil Gittoes & Sarah Davis. (2016) Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. Bone 89, pages 52-58.
Crossref
Crossref
M. Feudjo-Tepie, S. Ferguson, A. Roddam, A. Taylor, J. Bayly & C. Critchlow. (2015) Comorbidities, bone-sparing agent prescription history and their determinants among postmenopausal women in UK primary care settings: a retrospective database study. Archives of Osteoporosis 10:1.
Crossref
Crossref
R. Di Bari, C. Grippaudo & R. Deli. (2014) Bifosfonati e terapia ortodontica: implicazioni cliniche. Dental Cadmos 82:9, pages 614-621.
Crossref
Crossref
Sri Harsha Tella & J. Christopher Gallagher. (2014) Prevention and treatment of postmenopausal osteoporosis. The Journal of Steroid Biochemistry and Molecular Biology 142, pages 155-170.
Crossref
Crossref
Jean-Yves Reginster & Olivier BruyèreMichael R McClung. 2013. Osteoporosis. Osteoporosis
70
83
.
J. Yates. (2012) A meta-analysis characterizing the dose–response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Osteoporosis International 24:1, pages 253-262.
Crossref
Crossref
Robert B Hopkins, Ron Goeree, Eleanor Pullenayegum, Jonathan D Adachi, Alexandra Papaioannou, Feng Xie & Lehana Thabane. (2011) The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskeletal Disorders 12:1.
Crossref
Crossref
L. Xu, K.-S. Tsai, G. S. Kim, Y. Wu, P. Vincendon, A. A. Chines & G. D. Constantine. (2010) Efficacy and safety of bazedoxifene in postmenopausal Asian women. Osteoporosis International 22:2, pages 559-565.
Crossref
Crossref
J. Christopher Gallagher & Jeffrey P. Levine. (2011) Preventing osteoporosis in symptomatic postmenopausal women. Menopause 18:1, pages 109-118.
Crossref
Crossref
Catherine Van PoznakRosemary A. HannonJohn R. MackeyMario CamponeJustus P. ApffelstaedtGlen ClackDavid BarlowAndreas MakrisRichard Eastell. (2010) Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial. Journal of Clinical Oncology 28:6, pages 967-975.
Crossref
Crossref
Mone Zaidi, Charles H. Turner, Ernesto Canalis, Roberto Pacifici, Li Sun, Jameel Iqbal, X. Edward Guo, Stuart Silverman, Solomon Epstein & Clifford J. Rosen. (2009) Bone loss or lost bone: Rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss. Current Osteoporosis Reports 7:4, pages 118-126.
Crossref
Crossref
Louis-Georges Ste-Marie, Jacques P. Brown, John F. Beary, Ellen Matzkin, Lynn M. Darbie, David E. Burgio & Artur J. Racewicz. (2009) Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. Clinical Therapeutics 31:2, pages 272-285.
Crossref
Crossref
Cesar E. Fernandes, Cristiano Zerbini, Luís A. Russo, Marco A. Albernaz, Sergi R. Eis, Vera L. Szejnfeld & Luciano M. Pompei. (2009) Effects of Short-Term Risedronate on Bone Resorption and Patient Satisfaction in Postmenopausal Osteoporosis Patients. Journal of Clinical Densitometry 12:1, pages 77-83.
Crossref
Crossref
Wendy Rogers & Angela Ballantyne. (2008) When is sex-specific research appropriate?. IJFAB: International Journal of Feminist Approaches to Bioethics 1:2, pages 36-57.
Crossref
Crossref
George A Wells, Ann Cranney, Joan Peterson, Michel Boucher, Beverley Shea, Vivian Welch, Doug Coyle & Peter Tugwell. (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Cristina Mariano Ruas Brandão, Marina Guimarães Lima, Anderson Lourenço da Silva, Graziele Dias Silva, Augusto Afonso Guerra Jr. & Francisco de Assis Acúrcio. (2008) Treatment of postmenopausal osteoporosis in women: a systematic review. Cadernos de Saúde Pública 24:suppl 4, pages s592-s606.
Crossref
Crossref
S. Epstein. (2007) Is treatment of early postmenopausal women with bisphosphonates justified?. International Journal of Clinical Practice 61:6, pages 963-971.
Crossref
Crossref
Mark Marunick & Sara Gordon. (2006) Prosthodontic treatment during active osteonecrosis related to radiation and bisphosphonate therapy: A clinical report. The Journal of Prosthetic Dentistry 96:1, pages 7-12.
Crossref
Crossref
Raja S Bobba, Karen Beattie, Bill Parkinson, Dinesh Kumbhare & Jonathan D Adachi. (2006) Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease. Drug Safety 29:12, pages 1133-1152.
Crossref
Crossref
Paul D Miller, Christian Roux, Steven Boonen, Ian P Barton, Lisa E Dunlap & David E Burgio. (2005) Safety and Efficacy of Risedronate in Patients With Age-Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials. Journal of Bone and Mineral Research 20:12, pages 2105-2115.
Crossref
Crossref